ArticlePloS one2013
Quantifying cancer absolute risk and cancer mortality in the presence of competing events after a myotonic dystrophy diagnosis.
Article in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Cancer phenotype in myotonic dystrophy patients: Results from a meta-analysis.Muscle & nerve · 2018Pooled it
- Myotonic dystrophy type 1 as a cancer predisposition syndrome: A case report of quadruple primary malignancies with review of the literature.Gynecologic oncology reports · 2026Article
- Myotonic dystrophy type 1: clinical diversity, molecular insights and therapeutic perspectives.Nature reviews. Neurology · 2025Review
- Mortality Trends and Causes of Death in Myotonic Dystrophy Type 1 Patients From the UK Clinical Practice Research Datalink.Muscle & nerve · 2025Article
- Therapeutic advances in type 1 myotonic dystrophy complicated with type 2 diabetes mellitus.Frontiers in neurology · 2025Review
- Frequency and type of cancers in myotonic dystrophy: A retrospective cross-sectional study.Muscle & nerve · 2023Article
- Cancer and Myotonic Dystrophy.Journal of clinical medicine · 2023Review
- Nationwide incidence of myotonic dystrophy type 1 and the status of multi-organ involvement.Journal of neurology · 2022Article
- Diabetes, metformin and cancer risk in myotonic dystrophy type I.International journal of cancer · 2020Article
- Survival patterns and cancer determinants in families with myotonic dystrophy type 1.European journal of neurology · 2019Article
- Uveal Melanoma Associated With Myotonic Dystrophy: A Report of 6 Cases.JAMA ophthalmology · 2018Article
- Benign and malignant tumors in the UK myotonic dystrophy patient registry.Muscle & nerve · 2018Article
- Pigmentation phenotype, photosensitivity and skin neoplasms in patients with myotonic dystrophy.European journal of neurology · 2017Article
- A population-based survey of risk for cancer in individuals diagnosed with myotonic dystrophy.Muscle & nerve · 2016Article
- Brain tumors in patients with myotonic dystrophy: a population-based study.European journal of neurology · 2016Article
- Increased risk of tumor in DM1 is not related to exposure to common lifestyle risk factors.Journal of neurology · 2016Article
- Muscle wasting in myotonic dystrophies: a model of premature aging.Frontiers in aging neuroscience · 2015Review
- Myotonic dystrophy.Neurologic clinics · 2014Review
- RAREAACE clinical case reportsArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Recent studies show that patients with myotonic dystrophy (DM) have an increased risk of specific malignancies, but estimates of absolute cancer risk accounting for competing events are lacking. Using the Swedish Patient Registry, we identified 1,081 patients with an inpatient and/or outpatient diagnosis of DM between 1987 and 2007. Date and cause of death and date of cancer diagnosis were extracted from the Swedish Cause of Death and Cancer Registries. We calculated non-parametric estimates of absolute cancer risk and cancer mortality accounting for the high non-cancer competing mortality associated with DM. Absolute cancer risk after DM diagnosis was 1.6% (95% CI=0.4-4%), 5% (95% CI=3-9%) and 9% (95% CI=6-13%) at ages 40, 50 and 60 years, respectively. Females had a higher absolute risk of all cancers combined than males: 9% (95% CI=4-14), and 13% (95% CI=9-20) vs. 2% (95%CI= 0.7-6) and 4% (95%CI=2-8) by ages 50 and 60 years, respectively) and developed cancer at younger ages (median age =51 years, range=22-74 vs. 57, range=43-84, respectively, p=0.02). Cancer deaths accounted for 10% of all deaths, with an absolute cancer mortality risk of 2% (95%CI=1-4.5%), 4% (95%CI=2-6%), and 6% (95%CI=4-9%) by ages 50, 60, and 70 years, respectively. No gender difference in cancer-specific mortality was observed (p=0.6). In conclusion, cancer significantly contributes to morbidity and mortality in DM patients, even after accounting for high competing DM mortality from non-neoplastic causes. It is important to apply population-appropriate, validated cancer screening strategies in DM patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.